Are $3M gene ther­a­pies the new nor­mal? Ex­perts say blue­bird will be a test case for a mar­ket ready for prime time

Drug pric­ing ex­perts gen­er­al­ly agree that blue­bird bio’s two re­cent­ly ap­proved gene ther­a­pies and their mul­ti­mil­lion-dol­lar price tags aren’t go­ing to be one-offs as a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER